by Maria Zannes | Mar 25, 2026 | Press Releases
Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of “CyPath® Lung in Practice” webinar series focuses on need for greater certainty when diagnosing indeterminate...
by Maria Zannes | Mar 17, 2026 | Press Releases
CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported physician’s decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasive CyPath® Lung...
by Maria Zannes | Mar 13, 2026 | Press Releases
Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by physicians and...
by Maria Zannes | Mar 10, 2026 | Press Releases
Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study SAN ANTONIO, TX...
by Maria Zannes | Mar 3, 2026 | Press Releases
Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma...
by Maria Zannes | Feb 25, 2026 | Press Releases
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung SAN ANTONIO, TX – February 25, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and...
